Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer’s COVID-19 Vaccine Data In Young Children Could Place US FDA In Awkward Position Again

Jan 20 2022

• By Derrick Gingery

Child vaccination — More Pfizer data on the efficacy of its COVID-19 vaccine in children younger than 5 is expected in the coming months. • Source: Alamy

Related Content

With Pfizer EUA For 5-11 And Moderna Delay For Adolescents, US FDA Walks Myocarditis Tightrope

Nov 01 2021

Moderna COVID-19 Vaccine: Booster Study Hits Only One Of Two Immunogenicity Endpoints

Oct 13 2021

US FDA Vaccination Rate Exceeds 96%, But Will It Lead To More In-Office Work?

Dec 06 2021

COVID Vaccine Authorization Changes Without Advisory Committee Becoming More Common

Jan 04 2022

ACIP Upgrades Child Vaccine Booster Recommendation To ‘Should’

Jan 06 2022

Related Companies

Pfizer Inc.

BioNTech SE

Moderna, Inc.

Additional Topics

United States Coronavirus COVID-19 Vaccines Clinical Trials Drug Approval Standards Regulation Research & Development BioPharmaceutical

More from Vaccines

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.